219 related articles for article (PubMed ID: 16399578)
1. Adoptive transfer of allogeneic antigen-specific T cells.
Riddell SR; Bleakley M; Nishida T; Berger C; Warren EH
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):9-12. PubMed ID: 16399578
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
3. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
[TBL] [Abstract][Full Text] [Related]
4. [Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].
Tanaka J
Nihon Rinsho; 2003 Sep; 61(9):1512-9. PubMed ID: 14515717
[TBL] [Abstract][Full Text] [Related]
5. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
6. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
8. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
9. The allogeneic graft-versus-cancer effect.
Ringdén O; Karlsson H; Olsson R; Omazic B; Uhlin M
Br J Haematol; 2009 Dec; 147(5):614-33. PubMed ID: 19735262
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
11. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
Falkenburg JH; Willemze R
Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
13. [Antigen-specific allogeneic immunotherapy--selective augmentation of GVL effects].
Akatsuka Y
Gan To Kagaku Ryoho; 2008 May; 35(5):713-9. PubMed ID: 18487905
[TBL] [Abstract][Full Text] [Related]
14. [Allorecognition of the recipient after hematopoietic transplantation].
Tiberghien P; Robinet E; Ferrand C; Saas P; Hervé P
Bull Cancer; 2003; 90(8-9):706-10. PubMed ID: 14609760
[TBL] [Abstract][Full Text] [Related]
15. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response.
Takami A; Sugimori C; Feng X; Yachie A; Kondo Y; Nishimura R; Kuzushima K; Kotani T; Asakura H; Shiobara S; Nakao S
Bone Marrow Transplant; 2004 Oct; 34(8):703-9. PubMed ID: 15322566
[TBL] [Abstract][Full Text] [Related]
16. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
17. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
Hartwig UF; Nonn M; Khan S; Link I; Huber C; Herr W
Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
[TBL] [Abstract][Full Text] [Related]
18. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Matthes-Martin S; Richard C; Lion T; Fuhrer M; Hamprecht K; Handgretinger R; Peters C; Schuster FR; Beck R; Schumm M; Lotfi R; Jahn G; Lang P
Br J Haematol; 2006 Jul; 134(1):64-76. PubMed ID: 16803570
[TBL] [Abstract][Full Text] [Related]
19. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
[TBL] [Abstract][Full Text] [Related]
20. Minor histocompatibility antigens--targets of graft versus leukemia responses.
Riddell SR; Murata M; Bryant S; Warren EH
Int J Hematol; 2002 Aug; 76 Suppl 2():155-61. PubMed ID: 12430918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
